Literature DB >> 20014018

Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease.

Caroll J Beltrán1, Lucía E Núñez, David Díaz-Jiménez, Nancy Farfan, Enzo Candia, Claudio Heine, Francisco López, María Julieta González, Rodrigo Quera, Marcela A Hermoso.   

Abstract

BACKGROUND: ST2 has been proposed to be a regulator of inflammation and Th1/Th2 balance. ST2L is the IL-33 membrane receptor and belongs to the IL-1R family. The soluble variant, ST2s, is identical to the extracellular region of ST2L and competes for IL-33 binding, inhibiting receptor signaling. Although ST2s has been associated with inflammatory processes in patients with sepsis, trauma, asthma, and autoimmunity, until now there are no reported studies showing the role of ST2/IL-33 in inflammatory bowel disease (IBD).
METHODS: Expression of ST2 and IL-33 was determined in serum and colonic biopsies from IBD patients. ST2 transcript and protein was determined by reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA)/immunoblot, respectively, and IL-33 protein by ELISA. Intestinal mucosa localization of ST2 and IL-33 was conducted by immunofluorescence.
RESULTS: ST2s transcript in the colonic mucosa was mainly expressed in UC patients rather than Crohn's disease or control; however, ST2L mRNA remained constant in all samples. Total ST2 protein was significantly higher in mucosa samples from patients with active UC, with a predominant induction of ST2s that strongly correlates with serum ST2 levels. Mucosa IL-33 levels were higher in UC patients and serum levels were barely detected in all patient groups. ST2 and IL-33 are both abundantly expressed in the cytoplasm of epithelial cells of control subjects; however, in ulcerative colitis patients ST2 decreases and IL-33 showed cytoplasm-nuclear redistribution.
CONCLUSIONS: The novel association between the ST2/IL-33 system and IBD seems to identify that variations in this axis might regulate the inflammatory process in these diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20014018     DOI: 10.1002/ibd.21175

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  105 in total

1.  Quantitative phosphoproteomic analysis of IL-33-mediated signaling.

Authors:  Sneha M Pinto; Raja Sekhar Nirujogi; Pamela Leal Rojas; Arun H Patil; Srikanth S Manda; Yashwanth Subbannayya; Juan Carlos Roa; Aditi Chatterjee; T S Keshava Prasad; Akhilesh Pandey
Journal:  Proteomics       Date:  2015-01       Impact factor: 3.984

2.  IL-33 Signaling Protects from Murine Oxazolone Colitis by Supporting Intestinal Epithelial Function.

Authors:  Amanda Waddell; Jefferson E Vallance; Preston D Moore; Amy T Hummel; David Wu; Shiva K Shanmukhappa; Lin Fei; M Kay Washington; Phillip Minar; Lori A Coburn; Susumu Nakae; Keith T Wilson; Lee A Denson; Simon P Hogan; Michael J Rosen
Journal:  Inflamm Bowel Dis       Date:  2015-12       Impact factor: 5.325

3.  Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts.

Authors:  Jon Sponheim; Jürgen Pollheimer; Trine Olsen; Johanna Balogh; Clara Hammarström; Tamara Loos; Monika Kasprzycka; Dag Reidar Sørensen; Hogne Røed Nilsen; Axel M Küchler; Morten H Vatn; Guttorm Haraldsen
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

Review 4.  IL-33/ST2 Axis in Organ Fibrosis.

Authors:  Ourania S Kotsiou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Front Immunol       Date:  2018-10-24       Impact factor: 7.561

5.  IL-33 Drives Eosinophil Infiltration and Pathogenic Type 2 Helper T-Cell Immune Responses Leading to Chronic Experimental Ileitis.

Authors:  Carlo De Salvo; Xiao-Ming Wang; Luca Pastorelli; Benedetta Mattioli; Sara Omenetti; Kristine A Buela; Saleem Chowdhry; Rekha R Garg; Wendy A Goodman; Alex Rodriguez-Palacios; Dirk E Smith; Derek W Abbott; Fabio Cominelli; Giorgos Bamias; Wei Xin; James J Lee; Maurizio Vecchi; Theresa T Pizarro
Journal:  Am J Pathol       Date:  2016-02-22       Impact factor: 4.307

6.  Soluble ST2: a new and promising activity marker in ulcerative colitis.

Authors:  David Díaz-Jiménez; Lucía E Núñez; Caroll J Beltrán; Enzo Candia; Cristóbal Suazo; Manuel Alvarez-Lobos; María-Julieta González; Marcela A Hermoso; Rodrigo Quera
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

7.  TGF-β limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function.

Authors:  Reena Rani; Alan G Smulian; David R Greaves; Simon P Hogan; De'Broski R Herbert
Journal:  Eur J Immunol       Date:  2011-05-27       Impact factor: 5.532

8.  Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation.

Authors:  Luca Pastorelli; Carlo De Salvo; Marissa A Cominelli; Maurizio Vecchi; Theresa T Pizarro
Journal:  Therap Adv Gastroenterol       Date:  2011-09       Impact factor: 4.409

9.  IL-33 activates tumor stroma to promote intestinal polyposis.

Authors:  Rebecca L Maywald; Stephanie K Doerner; Luca Pastorelli; Carlo De Salvo; Susan M Benton; Emily P Dawson; Denise G Lanza; Nathan A Berger; Sanford D Markowitz; Heinz-Josef Lenz; Joseph H Nadeau; Theresa T Pizarro; Jason D Heaney
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

10.  Interleukin-33 exacerbates acute colitis via interleukin-4 in mice.

Authors:  Peter N Pushparaj; Dong Li; Mousa Komai-Koma; Rodrigo Guabiraba; James Alexander; Charles McSharry; Damo Xu
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.